Publications in collaboration with researchers from Hammersmith Hospital (4)

2022

  1. First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study

    British Journal of Cancer, Vol. 126, Núm. 11, pp. 1548-1554

  2. Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC

    ESMO Open, Vol. 7, Núm. 3

2021

  1. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 4, pp. 273-284

2020

  1. Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study

    Annals of Oncology, Vol. 31, Núm. 9, pp. 1160-1168